Powerup Acquisition CORP S-1 registration statements

Aspire Biopharma Holdings, Inc. is registering for resale up to 159,090,906 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock.

Aspire Biopharma Holdings, Inc. reports significant net losses and going concern doubt, while facing Nasdaq delisting and substantial shareholder dilution from recent financing activities.

Aspire Biopharma Holdings, Inc. files S-1/A to register up to 147 million shares for resale, reporting significant losses and going concern doubt despite positive aspirin clinical trial results.

Aspire Biopharma Holdings, Inc. filed an S-1 registration statement for the resale of up to 147 million common shares underlying convertible promissory notes, while reporting significant losses and a going concern doubt.

Aspire Biopharma Holdings seeks to register the resale of over 11 million shares by selling securityholders, including shares underlying warrants and those issued in connection with a settlement agreement.

Aspire Biopharma Holdings files for the resale of up to 3.15 million shares of common stock following its business combination, including shares issued as commitment shares and those reserved for conversion of convertible debentures.